- Home
- PFG vs INCY Comparison
PFG vs INCY Comparison
Compare PFG & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFG
- INCY
- Stock Information
- Founded
- PFG 1879
- INCY 1991
- Country
- PFG United States
- INCY United States
- Employees
- PFG N/A
- INCY N/A
- Industry
- PFG Specialty Insurers
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- PFG Finance
- INCY Health Care
- Exchange
- PFG Nasdaq
- INCY Nasdaq
- Market Cap
- PFG 16.3B
- INCY 13.4B
- IPO Year
- PFG N/A
- INCY 1993
- Fundamental
- Price
- PFG $72.14
- INCY $58.21
- Analyst Decision
- PFG Hold
- INCY Hold
- Analyst Count
- PFG 14
- INCY 20
- Target Price
- PFG $84.71
- INCY $74.00
- AVG Volume (30 Days)
- PFG 1.7M
- INCY 2.3M
- Earning Date
- PFG 04-24-2025
- INCY 04-29-2025
- Dividend Yield
- PFG 4.04%
- INCY N/A
- EPS Growth
- PFG N/A
- INCY N/A
- EPS
- PFG N/A
- INCY 0.15
- Revenue
- PFG $16,127,700,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- PFG $2.61
- INCY $12.21
- Revenue Next Year
- PFG $5.22
- INCY $9.20
- P/E Ratio
- PFG $10.36
- INCY $345.39
- Revenue Growth
- PFG 18.02
- INCY 14.76
- 52 Week Low
- PFG $68.39
- INCY $50.35
- 52 Week High
- PFG $91.98
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- PFG 38.04
- INCY 40.69
- Support Level
- PFG $71.27
- INCY $57.05
- Resistance Level
- PFG $74.64
- INCY $59.95
- Average True Range (ATR)
- PFG 3.91
- INCY 2.76
- MACD
- PFG -0.59
- INCY 0.18
- Stochastic Oscillator
- PFG 20.75
- INCY 46.45
About PFG Principal Financial Group Inc
Principal Financial Group Inc is a financial services provider. It offers various financial products and services including retirement, asset management, and workplace benefits and protection solutions to individuals and institutional clients. The company, along with its subsidiaries, operates in the following reportable segments; Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection. Maximum revenue is generated from the Retirement and Income Solutions segment which provides workplace savings and retirement solutions, banking, trust and custodial services, individual variable annuities (including RILAs), pension risk transfer, and investment services to businesses, their employees, and other individuals.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.